The Effect of Hirodoid Cream on Ecchymosis and Edema around Eyes after Rhinoplasty.
Abstract
[BACKGROUND] Several methods have been used to decrease the periorbital edema and ecchymosis after rhinoplasty. In this study, we evaluated the efficacy of hirudoid and dexamethasone in reduction of the periorbital edema and ecchymosis.
[METHODS] Sixty patients who underwent primary rhinoplasty were randomly divided into 3 groups. Group H received hirudoid cream, 3 times per day for 5 days from postoperative-day (POD). Group D received 10 mg of dexamethasone IV, immediately before surgery; and group C (control) received neither dexamethasone nor hirudoid. Two surgeons who were unaware of administered medications rated the severity of edema and intensity of ecchymosis, on 2, 5, and 7 POD.
[RESULTS] On 2 POD, the edema in group D was significantly lower than groups H and C; but there was no significant difference in severity and intensity of ecchymosis between 3 groups. On 7 POD, the intensity of ecchymosis was significantly lower in group H in comparison to group C. When the difference between 2 and 7 POD was evaluated, the resolution of severity of edema and intensity of ecchymosis was significantly better in group H (<0.001).
[CONCLUSION] Hirudoid was shown to be effective in reducing edema and ecchymosis after rhinoplasty. The use of dexamethasone was effective in prevention of periorbital edema at early postoperative days, but it was not effective on resolution of ecchymosis.
[METHODS] Sixty patients who underwent primary rhinoplasty were randomly divided into 3 groups. Group H received hirudoid cream, 3 times per day for 5 days from postoperative-day (POD). Group D received 10 mg of dexamethasone IV, immediately before surgery; and group C (control) received neither dexamethasone nor hirudoid. Two surgeons who were unaware of administered medications rated the severity of edema and intensity of ecchymosis, on 2, 5, and 7 POD.
[RESULTS] On 2 POD, the edema in group D was significantly lower than groups H and C; but there was no significant difference in severity and intensity of ecchymosis between 3 groups. On 7 POD, the intensity of ecchymosis was significantly lower in group H in comparison to group C. When the difference between 2 and 7 POD was evaluated, the resolution of severity of edema and intensity of ecchymosis was significantly better in group H (<0.001).
[CONCLUSION] Hirudoid was shown to be effective in reducing edema and ecchymosis after rhinoplasty. The use of dexamethasone was effective in prevention of periorbital edema at early postoperative days, but it was not effective on resolution of ecchymosis.
추출된 의학 개체 (NER)
| 유형 | 영어 표현 | 한국어 / 풀이 | UMLS CUI | 출처 | 등장 |
|---|---|---|---|---|---|
| 시술 | rhinoplasty
|
코성형술 | dict | 4 | |
| 해부 | Eyes
|
scispacy | 1 | ||
| 해부 | hirudoid
|
scispacy | 1 | ||
| 합병증 | Edema
|
scispacy | 1 | ||
| 합병증 | periorbital edema
|
scispacy | 1 | ||
| 약물 | Cream
|
C0700385
Dairy Cream
|
scispacy | 1 | |
| 약물 | dexamethasone
|
C0011777
dexamethasone
|
scispacy | 1 | |
| 약물 | [BACKGROUND]
|
scispacy | 1 | ||
| 약물 | hirudoid
|
scispacy | 1 | ||
| 약물 | 7 POD
|
scispacy | 1 | ||
| 약물 | [CONCLUSION] Hirudoid
|
scispacy | 1 | ||
| 질환 | Ecchymosis
|
C0013491
Ecchymosis
|
scispacy | 1 | |
| 질환 | Edema
|
C0013604
Edema
|
scispacy | 1 | |
| 질환 | periorbital edema
|
C0151205
Periorbital edema
|
scispacy | 1 | |
| 질환 | POD
→ postoperative-day
|
scispacy | 1 | ||
| 기타 | patients
|
scispacy | 1 |
🔗 함께 등장하는 도메인
이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들
관련 논문
- The impact of three-dimensional simulation and virtual reality technologies on surgical decision-making and postoperative satisfaction in aesthetic surgery: a preliminary study.
- Aesthetically ideal noses created using a single artificial intelligence model: Validating literature and exploring ethnic differences.
- Septocolumellar strut technique: Tip stability and aesthetic outcomes in rhinoplasty.
- Implications of Dermatologic Disorders in Facial Cosmetic Surgery: A Systematic Review.
- Factors on Quality of Life Improvement in Septorhinoplasty: Prospective Evaluation Using the Functional Rhinoplasty Outcome Inventory 17 and Its Minimally Important Difference.